CDO/CRO/CMO

CDMO Partner for customer success, from the R&D of the raw materials for pharmaceuticals to production, the total solution is offered

Since its establishment, Sungwun Pharmacopia has been conducting many CDO and CRO projects with global pharmaceutical companies both domestically and internationally, and has accumulated a high level of experience in commissioned R&D/consignment production, carrying out dozens of technology transfers, patent applications, and various government tasks. Based on this experience and high level of R&D ability, we will be a CDMO partner for the success of our customers who provide integrated solutions that take into account details from R&D to production.
  • New Candidate Materials / APIs
    / Semiconductors, Electronic Materials
    / Cosmetics ingredients
  • 위탁개발CDO
    • - Process Development and Design
    • - Setting of Synthetic Path
    • - Development of Analysis method and Validation
    위탁연구CRO
    • - Research of Process and Optimization
    • - Providing Analysis Service
    • - Technical Documentation and Authorization Support
    위탁생산CMO
    • - Scale-Up / Pilot Production
    • - Commercial Scale Production
    • - Production Support and Transfer of Technology Service

  • “ End - To - End ” CDMO Service

    From sourcing raw materials to process
    development, analysis services, scale-up
    and Commercial production, We offer
    customized End-To-End CDMO services
    depending on customer needs.
  • Company with Profession
    • - Establishment of a platform for developing bio-drug raw materials and synthetic raw materials
    • - GMP Quality Control System and Expert Analysis Test Equipment
  • A Well-Recognized Company
    • - Ministry of Health and Welfare, awared by the Food and Drug Administration as an excellent raw material drug manufacturer (2017)
    • - Awarded of "Excellent Technical Skills by Small-Giant Enterprise Award" by the Ministry of Food and Drug Safety (2018)
    • - Designated as an "Action Plan Company" by the Ministry of Health and Welfare (2017) regarding on the New Southern Policy
  • Company with Solid Infrastructure
    • - 2 GMP-Graded Production Plants(API Synthetic - 2 Lines, Chemical Production 2 Lines)
    • - R&D Center in South Korea for Synthetic and Bio
    • - R&D Center in Indonesia for Synthetic and Formulation
  • Company with Extensive Experience
    • - Development and technology transfer of multiple raw materials and intermediates
    • - CDO and CMO projects with domestic pharmaceutical companies and global pharmaceutical companies
    • - Establishment of joint venture with PT. Kimia Farma, the largest national pharmaceutical company in Indonesia